Last reviewed · How we verify
Asthma therapies
Asthma therapies from Genentech include multiple marketed drugs that work through different mechanisms to reduce airway inflammation and improve lung function in asthma patients.
Asthma therapies from Genentech include multiple marketed drugs that work through different mechanisms to reduce airway inflammation and improve lung function in asthma patients. Used for Moderate to severe allergic asthma, Moderate to severe eosinophilic asthma, Moderate to severe atopic dermatitis with asthma.
At a glance
| Generic name | Asthma therapies |
|---|---|
| Sponsor | Genentech, Inc. |
| Drug class | Monoclonal antibodies (multiple agents with different targets) |
| Target | IgE, IL-5, IL-4 receptor alpha (varies by specific agent) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | FDA-approved |
Mechanism of action
Genentech's asthma portfolio includes biologics such as omalizumab (anti-IgE monoclonal antibody), reslizumab (anti-IL-5 monoclonal antibody), and dupilumab (anti-IL-4 receptor alpha monoclonal antibody), each targeting specific inflammatory pathways involved in asthma pathogenesis. These agents reduce eosinophil recruitment, IgE-mediated mast cell activation, and type 2 inflammatory responses to improve asthma control and reduce exacerbations.
Approved indications
- Moderate to severe allergic asthma
- Moderate to severe eosinophilic asthma
- Moderate to severe atopic dermatitis with asthma
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Nasopharyngitis
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
- High Flow Nasal Cannula Rates in Pediatric Asthma (NA)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Use of fenoTRACK Device for Monitoring Changes of Fractional Exhaled Nitric Oxide (FeNO) in Uncontrolled Asthma Subjects and Controlled Asthma Subjects
- Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
- Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Asthma therapies CI brief — competitive landscape report
- Asthma therapies updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI